Published in Hepatology on May 01, 2009
TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene (2009) 2.33
Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One (2011) 1.98
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 1.74
miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology (2010) 1.66
MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol (2010) 1.62
Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ (2013) 1.60
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology (2011) 1.52
MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res (2010) 1.51
Development of the human cancer microRNA network. Silence (2010) 1.43
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol (2011) 1.38
Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem (2010) 1.22
MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology (2011) 1.22
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.14
Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One (2013) 1.11
Coordinated effects of microRNA-494 induce G₂/M arrest in human cholangiocarcinoma. Cell Cycle (2012) 1.08
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget (2015) 1.07
MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol (2009) 1.02
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One (2013) 1.00
Epigenetics: principles and practice. Dig Dis (2011) 0.98
miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol (2012) 0.98
MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci (2012) 0.98
miRNAs in breast cancer tumorigenesis (Review). Oncol Rep (2011) 0.96
miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur Heart J (2013) 0.95
microRNA therapies in cancer. Mol Cell Ther (2014) 0.95
MiR-21 plays an important role in radiation induced carcinogenesis in BALB/c mice by directly targeting the tumor suppressor gene Big-h3. Int J Biol Sci (2011) 0.94
Regulation of cardiac microRNAs by serum response factor. J Biomed Sci (2011) 0.93
miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res (2014) 0.93
Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS One (2012) 0.92
Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther (2015) 0.92
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
A meta-analysis of microRNA expression in liver cancer. PLoS One (2014) 0.90
The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment. Mol Biol Int (2011) 0.90
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J (2014) 0.89
Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands. BMC Genomics (2010) 0.89
Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget (2015) 0.89
MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor. PLoS One (2015) 0.88
MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis (2012) 0.88
Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford) (2012) 0.87
MicroRNAs in biliary diseases. World J Gastroenterol (2012) 0.87
Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. Mol Cell Pharmacol (2011) 0.86
Stress-induced ECM alteration modulates cellular microRNAs that feedback to readjust the extracellular environment and cell behavior. Front Genet (2013) 0.84
Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol (2013) 0.83
MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. BMC Cancer (2014) 0.83
A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med (2015) 0.82
MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma. Int J Clin Exp Pathol (2015) 0.82
Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer (2015) 0.82
A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma. BMC Cancer (2015) 0.81
Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol Pharm (2016) 0.81
Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma. Sci Rep (2015) 0.81
A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma. BMC Cancer (2016) 0.81
MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways. World J Gastroenterol (2015) 0.81
Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Dig Dis Sci (2014) 0.81
Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression. Oncol Lett (2014) 0.80
Inhibition of NF-κB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocelular apoptosis. Sci Rep (2015) 0.80
Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expr (2014) 0.80
MicroRNAs in Cholangiopathies. Curr Pathobiol Rep (2014) 0.80
miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res (2015) 0.80
MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. J Clin Med (2015) 0.79
A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int (2012) 0.79
Inferring the perturbed microRNA regulatory networks in cancer using hierarchical gene co-expression signatures. PLoS One (2013) 0.79
Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One (2016) 0.79
The significance of genetics for cholangiocarcinoma development. Ann Transl Med (2013) 0.78
The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. Front Genet (2014) 0.78
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc (2016) 0.78
MicroRNAs and benign biliary tract diseases. Semin Liver Dis (2015) 0.78
Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics (2010) 0.77
TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLoS One (2015) 0.77
Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci (2016) 0.76
Banking on the future: biobanking for "omics" approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand. Parasitol Int (2011) 0.76
Illustrating the interplay between the extracellular matrix and microRNAs. Int J Exp Pathol (2014) 0.76
Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PLoS One (2014) 0.76
Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget (2016) 0.75
New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma. Am J Transl Res (2015) 0.75
The real-time dynamic monitoring of microRNA function in cholangiocarcinoma. PLoS One (2014) 0.75
miR-21 and KLF4 jointly augment epithelial‑mesenchymal transition via the Akt/ERK1/2 pathway. Int J Oncol (2017) 0.75
Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int (2016) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
The Emerging Role of miRNAs and Their Clinical Implication in Biliary Tract Cancer. Gastroenterol Res Pract (2016) 0.75
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer (2016) 0.75
A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep (2016) 0.75
Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. Int J Med Sci (2017) 0.75
Expression and prognostic value of Ars2 in hepatocellular carcinoma. Int J Clin Oncol (2013) 0.75
Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model. Oncol Lett (2017) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene (2007) 7.02
Biliary tract cancers. N Engl J Med (1999) 6.36
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (2008) 4.38
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene (2002) 2.31
Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol (2006) 2.29
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene (2007) 2.14
Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene (2006) 2.10
miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res (2008) 2.09
Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene (1995) 2.05
Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol (2008) 2.03
Implications of micro-RNA profiling for cancer diagnosis. Oncogene (2006) 2.01
"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc (1995) 1.97
Surgical management of cholangiocarcinoma. Semin Liver Dis (2004) 1.75
Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med (1995) 1.46
Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol (2002) 1.29
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy? Biol Cell (2003) 1.23
Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res (2000) 1.23
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther (2005) 1.19
Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res (2006) 1.10
TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int (2007) 0.87
High level expression of tissue inhibitors of metalloproteinases-1,-2 and -3 in melanoma cells achieved by adenovirus mediated gene transfer. Adv Exp Med Biol (1998) 0.84
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Five years of GWAS discovery. Am J Hum Genet (2012) 12.97
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res (2007) 7.98
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Capture of authentic embryonic stem cells from rat blastocysts. Cell (2008) 6.60
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet (2012) 5.78
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Klf4 reverts developmentally programmed restriction of ground state pluripotency. Development (2009) 5.49
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res (2005) 4.77
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol (2007) 4.65
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet (2010) 4.58
VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors. Nucleic Acids Res (2011) 4.36
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res (2009) 4.25
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol (2003) 3.86
Strategies for improving attendance at medical grand rounds at an academic medical center. Mayo Clin Proc (2003) 3.71
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res (2005) 3.56
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell (2005) 3.44
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
A commentary on 'common SNPs explain a large proportion of the heritability for human height' by Yang et al. (2010). Twin Res Hum Genet (2010) 3.37
A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res (2009) 3.37
Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron (2002) 3.37
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem (2009) 3.34
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Cryptosporidiosis. N Engl J Med (2002) 3.24
HEN1 functions pleiotropically in Arabidopsis development and acts in C function in the flower. Development (2002) 3.24
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology (2006) 3.20
MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol (2009) 3.19
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 3.09
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Pitfalls of predicting complex traits from SNPs. Nat Rev Genet (2013) 3.06
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Lysosomes in cell death. Oncogene (2004) 3.00
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem (2007) 2.89
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81